Top

Published in:

Open Access 01-12-2022 | Vaccination | Research article

Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production

Authors: Michael Müller, Johann Volzke, Behnam Subin, Silke Müller, Martina Sombetzki, Emil C. Reisinger, Brigitte Müller-Hilke

Published in: BMC Medicine | Issue 1/2022

Abstract

Background

While vaccination programs against the severe acute respiratory syndrome virus 2 (SARS-CoV-2) are globally ongoing, disparate strategies for the deployment of spike antigen show varying effectiveness.

Methods

In order to explore this phenomenon, we sought to compare the early immune responses against AZD1222 and BNT162b2. SARS-CoV-2 seronegative participants received a single dose of either vaccine and were analyzed for immune cell, effector T cell, and antibody dynamics.

Results

AZD1222 induced transient leukopenia and major changes among innate and adaptive subpopulations. Both vaccines induced spike protein-specific effector T cells which were dominated by type 1 helper T cell responses following AZD1222 vaccination. A significant reduction of anti-inflammatory T cells upon re-stimulation was also restricted to AZD1222 vaccinees. While IgM and IgG were the dominant isotypes elicited by AZD1222, BNT162b2 led to a significant production of IgG and IgA.

Conclusions

Our results suggest that the strategy for spike protein delivery impacts on how and to what extent immune priming against the main SARS-CoV-2 antigen proceeds.

Available only for authorised users

Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4. https://doi.org/10.1016/S1473-3099(20)30120-1.CrossRefPubMedPubMedCentral

Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85–100. https://doi.org/10.1016/j.biochi.2020.09.018.CrossRefPubMedPubMedCentral

Hanrath AT, Payne BAI, Duncan CJA. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. J Infect. 2021;82(4):e29–30. https://doi.org/10.1016/j.jinf.2020.12.023.CrossRefPubMed

Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe acute respiratory syndrome coronavirus 2−specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020;26(7):1478–88. https://doi.org/10.3201/eid2607.200841.CrossRefPubMedPubMedCentral

Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227–30. https://doi.org/10.1126/science.abd7728.CrossRefPubMedPubMedCentral

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586(7830):578–82. https://doi.org/10.1038/s41586-020-2608-y.CrossRefPubMedPubMedCentral

Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586. https://doi.org/10.1016/j.ijpharm.2021.120586.CrossRefPubMedPubMedCentral

Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–9. https://doi.org/10.1038/s41586-021-03275-y.CrossRefPubMed

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577.CrossRefPubMed

10.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. https://doi.org/10.1016/S0140-6736(20)32661-1.CrossRefPubMedPubMedCentral

11.

Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875–7. https://doi.org/10.1016/S0140-6736(21)00448-7.CrossRefPubMedPubMedCentral

12.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23. https://doi.org/10.1056/NEJMoa2101765.CrossRefPubMed

13.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–91. https://doi.org/10.1016/S0140-6736(21)00432-3.CrossRefPubMedPubMedCentral

14.

Cele S, Gazy I, Jackson L, Hwa S-H, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593(7857):142–6. https://doi.org/10.1038/s41586-021-03471-w.CrossRefPubMed

15.

Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885–98. https://doi.org/10.1056/NEJMoa2102214.CrossRefPubMed

16.

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438–43. https://doi.org/10.1038/s41586-021-03402-9.CrossRefPubMed

17.

Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385(2):187–9. https://doi.org/10.1056/NEJMc2104974.CrossRefPubMed

18.

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–94. https://doi.org/10.1056/NEJMoa2108891.CrossRefPubMed

19.

Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397(10292):2331–3. https://doi.org/10.1016/S0140-6736(21)01290-3.CrossRefPubMedPubMedCentral

20.

Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics — developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–80. https://doi.org/10.1038/nrd4278.CrossRefPubMed

21.

Park JY, Kim B-J, Lee EJ, Park KS, Park HS, Jung SS, et al. Clinical features and courses of adenovirus pneumonia in healthy young adults during an outbreak among Korean military personnel. PLoS ONE. 2017;12(1):e0170592. https://doi.org/10.1371/journal.pone.0170592.CrossRefPubMedPubMedCentral

22.

Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naïve and pre-immunized mice. Gene Ther. 2005;12(5):427–36. https://doi.org/10.1038/sj.gt.3302347.CrossRefPubMed

23.

Wirth T, Hedman M, Makinen K, Manninen H, Immonen A, Vapalahti M, et al. Safety profile of plasmid/liposomes and virus vectors in clinical gene therapy. Curr Drug Saf. 2006;1(3):253–7. https://doi.org/10.2174/157488606777934440.CrossRefPubMed

24.

Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther. 2004;10(4):616–29. https://doi.org/10.1016/j.ymthe.2004.07.013.CrossRefPubMed

25.

Varnavski AN, Zhang Y, Schnell M, Tazelaar J, Louboutin J-P, Yu Q-C, et al. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol. 2002;76(11):5711–9. https://doi.org/10.1128/JVI.76.11.5711-5719.2002.CrossRefPubMedPubMedCentral

26.

Green AM, Harris E. Monocyte-plasmablast crosstalk during dengue. Cell Host Microbe. 2014;16(1):7–9. https://doi.org/10.1016/j.chom.2014.06.011.CrossRefPubMedPubMedCentral

27.

Kazer SW, Walker BD, Shalek AK. Evolution and diversity of immune responses during acute HIV infection. Immunity. 2020;53(5):908–24. https://doi.org/10.1016/j.immuni.2020.10.015.CrossRefPubMed

28.

Kwissa M, Nakaya HI, Onlamoon N, Wrammert J, Villinger F, Perng GC, et al. Dengue virus infection induces expansion of a CD14+CD16+ monocyte population that stimulates plasmablast differentiation. Cell Host Microbe. 2014;16(1):115–27. https://doi.org/10.1016/j.chom.2014.06.001.CrossRefPubMedPubMedCentral

29.

Gordon CL, Miron M, Thome JJC, Matsuoka N, Weiner J, Rak MA, et al. Tissue reservoirs of antiviral T cell immunity in persistent human CMV infection. J Exp Med. 2017;214(3):651–67. https://doi.org/10.1084/jem.20160758.CrossRefPubMedPubMedCentral

30.

Tian Y, Babor M, Lane J, Schulten V, Patil VS, Seumois G, et al. Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA. Nat Commun. 2017;8(1):1473. https://doi.org/10.1038/s41467-017-01728-5.CrossRefPubMedPubMedCentral

31.

Weiskopf D, Bangs DJ, Sidney J, Kolla RV, De Silva AD, de Silva AM, et al. Dengue virus infection elicits highly polarized CX3CR1 + cytotoxic CD4 + T cells associated with protective immunity. Proc Natl Acad Sci. 2015;112(31):E4256–63. https://doi.org/10.1073/pnas.1505956112.CrossRefPubMedPubMedCentral

32.

Hammarlund E, Thomas A, Amanna IJ, Holden LA, Slayden OD, Park B, et al. Plasma cell survival in the absence of B cell memory. Nat Commun. 2017;8(1):1781. https://doi.org/10.1038/s41467-017-01901-w.CrossRefPubMedPubMedCentral

33.

Sanz I, Wei C, Lee FE-H, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008;20(1):67–82. https://doi.org/10.1016/j.smim.2007.12.006.CrossRefPubMedPubMedCentral

34.

Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–40. https://doi.org/10.1038/mt.2008.200.CrossRefPubMed

35.

Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13:eabd2223. https://doi.org/10.1126/scitranslmed.abd2223.CrossRefPubMed

36.

Ciabattini A, Pastore G, Fiorino F, Polvere J, Lucchesi S, Pettini E, et al. Evidence of SARS-CoV-2-specific memory B cells six months after vaccination with the BNT162b2 mRNA vaccine. Front Immunol. 2021;12. https://doi.org/10.3389/fimmu.2021.740708.

37.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–78. https://doi.org/10.1016/S0140-6736(20)31604-4.CrossRefPubMedPubMedCentral

38.

Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. medRxiv. 2021:21257971. https://doi.org/10.1101/2021.05.30.21257971.

39.

Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021;12(1):3991. https://doi.org/10.1038/s41467-021-24285-4.CrossRefPubMedPubMedCentral

40.

Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599(7883):114–9. https://doi.org/10.1038/s41586-021-03944-y.CrossRefPubMedPubMedCentral

41.

Chan RWY, Liu S, Cheung JY, Tsun JGS, Chan KC, Chan KYY, et al. The mucosal and serological immune responses to the novel coronavirus (SARS-CoV-2) vaccines. Front Immunol. 2021;12. https://doi.org/10.3389/fimmu.2021.744887.

42.

Afkhami S, D’Agostino MR, Zhang A, Stacey HD, Marzok A, Kang A, et al. Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. bioRxiv. 2021:452721. https://doi.org/10.1101/2021.07.16.452721.

43.

Boyaka PN. Inducing Mucosal IgA: A challenge for vaccine adjuvants and delivery systems. J Immunol. 2017;199(1):9–16. https://doi.org/10.4049/jimmunol.1601775.CrossRefPubMed

44.

Eckmann L, Morzycka-Wroblewska E, Smith JR, Kagnoff MF. Cytokine-induced differentiation of IgA B cells: studies using an IgA expressing B-cell lymphoma. Immunology. 1992;76(2):235–41. http://www.ncbi.nlm.nih.gov/pubmed/1634247.PubMedPubMedCentral

45.

Moore KW, de Waal MR, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19(1):683–765. https://doi.org/10.1146/annurev.immunol.19.1.683.CrossRefPubMed

46.

Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med. 2007;204(2):239–43. https://doi.org/10.1084/jem.20070104.CrossRefPubMedPubMedCentral

47.

Yu Y, Ma X, Gong R, Zhu J, Wei L, Yao J. Recent advances in CD8+ regulatory T cell research (Review). Oncol Lett. 2018;15(6):8187–94. https://doi.org/10.3892/ol.2018.8378.CrossRefPubMedPubMedCentral

48.

Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol. 2020;38(9):1073–8. https://doi.org/10.1038/s41587-020-0631-z.CrossRefPubMed

49.

McInnes L, Healy J, Melville J. UMAP: uniform manifold approximation and projection for dimension reduction. 2018. http://arxiv.org/abs/1802.03426.

50.

Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347–8. https://doi.org/10.1016/S0140-6736(21)00527-4.CrossRefPubMedPubMedCentral

Title: Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production
Authors: Michael Müller
Johann Volzke
Behnam Subin
Silke Müller
Martina Sombetzki
Emil C. Reisinger
Brigitte Müller-Hilke
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Vaccination
SARS-CoV-2
COVID-19
Published in: BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-022-02240-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Early emergence of sexual dimorphism in offspring leukocyte telomere length was associated with maternal and children’s glucose metabolism—a longitudinal study

Contraceptive use and contraceptive counselling interventions for women of reproductive age with cancer: a systematic review and meta-analysis

Investigating causal relations between sleep duration and risks of adverse pregnancy and perinatal outcomes: linear and nonlinear Mendelian randomization analyses

Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients

Optimising a person-centred approach to stopping medicines in older people with multimorbidity and polypharmacy using the DExTruS framework: a realist review

Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment, and race and ethnicity for the United States 2000–2019